Management of Peripheral Arterial Occlusive Disease

Comprehensive Medical Therapy

The American Heart Association recommends that all patients with peripheral arterial disease (PAD) must receive guideline-directed medical therapy (GDMT) consisting of antiplatelet agents, high-intensity statins, blood pressure control with ACE inhibitors or ARBs, and structured exercise to reduce both cardiovascular events and limb-related complications 1
The American College of Cardiology recommends initiating either aspirin (75-325 mg daily) or clopidogrel (75 mg daily) immediately to reduce myocardial infarction, stroke, and vascular death in all symptomatic PAD patients 1
The American Heart Association suggests that for asymptomatic PAD patients (ABI ≤0.90), antiplatelet therapy is reasonable to reduce cardiovascular events 1
Dual antiplatelet therapy (aspirin plus clopidogrel) is not well-established for routine use but may be reasonable after lower extremity revascularization to reduce limb-related events 1

The American College of Cardiology recommends prescribing high-intensity statin therapy to all PAD patients regardless of baseline LDL-C levels 1, 2
The American Heart Association suggests targeting LDL-C <55 mg/dL (<1.4 mmol/L) with ≥50% reduction from baseline in all PAD patients, as they are at very high cardiovascular risk 3

The American Heart Association recommends starting ACE inhibitors or ARBs as first-line antihypertensive agents in all PAD patients with hypertension, regardless of baseline blood pressure 1, 3
The American College of Cardiology suggests targeting systolic blood pressure of 120-129 mmHg in most PAD patients, provided treatment is well tolerated 3
The American Heart Association advises avoiding lowering systolic blood pressure below 120 mmHg, as this may worsen limb perfusion and increase cardiovascular events (J-curve phenomenon) 3

The American Diabetes Association recommends controlling diabetes aggressively in PAD patients, as diabetes combined with reduced ABI predicts development of ischemic rest pain and ulceration 4
The American Heart Association suggests targeting HbA1c <7% while recognizing that diabetes control primarily reduces microvascular rather than PAD-specific complications 5

The American College of Sports Medicine recommends prescribing supervised exercise training at least 3 times weekly for a minimum of 30 minutes per session over at least 12 weeks as primary treatment for mild PAD 2
The American Heart Association suggests that walking should be the first-line training modality with high-intensity exercise for optimal results 2

The American College of Cardiology recommends prescribing cilostazol (phosphodiesterase III inhibitor) for symptomatic improvement in claudication and walking distance 1, 6, 2
The American Heart Association advises that cilostazol is contraindicated in patients with heart failure due to its mechanism of action 1

The American Heart Association mandates immediate and complete smoking cessation as it is vital for preventing disease progression and reducing cardiovascular events 1, 2

The American College of Cardiology already addressed hyperlipidemia above with statin therapy targeting LDL-C <55 mg/dL 3
The American Heart Association already addressed hypertension above with ACE inhibitor/ARB first-line therapy and BP target 120-129 mmHg 3
The American Diabetes Association already addressed diabetes above with HbA1c target <7% 5

The American College of Cardiology recommends measuring ankle-brachial index (ABI) and pulse volume recording (PVR) for initial diagnosis and follow-up 6
The American Heart Association suggests that duplex Doppler ultrasound is the initial study to evaluate arterial occlusive disease 6

The American College of Cardiology advises never delaying or substituting exercise therapy with medications alone—supervised exercise is as important as pharmacotherapy 3
The American Heart Association recommends avoiding dual RAS blockade (ACE inhibitor plus ARB combination) due to increased adverse events without additional benefit 3
The American College of Cardiology advises against aggressively lowering systolic BP below 120 mmHg, as this compromises limb perfusion 3

The American Heart Association recommends assessing medication adherence, limb symptoms, and cardiovascular risk factors at least annually 3
The American College of Cardiology suggests evaluating for left ventricular dysfunction, as 20-30% of PAD patients have concurrent heart failure 3
The American Heart Association advises monitoring for disease progression with periodic ABI measurements 6

The American Heart Association notes that the annual mortality rate in PAD patients is 4-6%, with a combined event rate for MI, stroke, and vascular death approximately 4-5% per year 4
The American College of Cardiology suggests that one-year mortality in critical limb ischemia is approximately 25%, rising to 45% in those requiring amputation 4
The American Heart Association advises that claudication symptoms usually remain stable without rapid progression in most patients 4
The American College of Cardiology notes that two clinical factors—reduced ABI and diabetes mellitus—predict development of ischemic rest pain and ulceration 4